NASDAQ:NRXS NeurAxis 5/20/2024 Earnings Report $2.52 -0.06 (-2.33%) Closing price 04:00 PM EasternExtended Trading$2.53 +0.01 (+0.40%) As of 06:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast NeurAxis EPS ResultsActual EPS-$0.32Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ANeurAxis Revenue ResultsActual Revenue$0.65 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ANeurAxis Announcement DetailsQuarterDate5/20/2024TimeN/AConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile NeurAxis Earnings HeadlinesNeurAxis (NASDAQ:NRXS) Coverage Initiated at Craig HallumJune 18, 2025 | americanbankingnews.comNeurAxis, Inc. Expands Insurance Coverage for IB-Stim Therapy, Enhancing Access for Patients with Abdominal PainJune 17, 2025 | quiverquant.comQA new rule goes live in July — and the banks are quietly cashing inA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big Banks have found a way to use a new asset as if it were cash. Not stocks. Not bonds. Not even the U.S. dollar. They now trust this asset more than the traditional financial system itself.June 26 at 2:00 AM | American Alternative (Ad)NeurAxis Announces New Medical Policy Coverage with Two Health Insurers, Adding 700,000 Covered LivesJune 17, 2025 | globenewswire.comNeurAxis Achieves Critical Milestone; Secures Key Academic Society Guidelines Recommendation for Treatment of Functional Abdominal Pain (FAP) in IBSJune 10, 2025 | finance.yahoo.comNeurAxis, Inc. Announces Inclusion of PENFS Technology in Pediatric Gastroenterology Guidelines for Functional Abdominal Pain TreatmentJune 10, 2025 | quiverquant.comQSee More NeurAxis Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like NeurAxis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NeurAxis and other key companies, straight to your email. Email Address About NeurAxisNeurAxis (NASDAQ:NRXS), a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.View NeurAxis ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Smith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting CycleBroadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record Highs Upcoming Earnings Bank of America (7/14/2025)Interactive Brokers Group (7/15/2025)America Movil (7/15/2025)Bank of New York Mellon (7/15/2025)Citigroup (7/15/2025)JPMorgan Chase & Co. (7/15/2025)Progressive (7/15/2025)Charles Schwab (7/15/2025)UnitedHealth Group (7/15/2025)Wells Fargo & Company (7/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
